GLP‑1 Weight‑Loss Drugs Linked to 30% Lower Breast
SkimNews Take
The observed reduction in breast cancer risk among GLP-1 users suggests a potential direct biological mechanism beyond weight loss alone, warranting further investigation into cellular pathways.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- GLP‑1 medications (including Ozempic, Wegovy, Mounjaro, Zepbound) were linked to a 30% lower breast cancer incidence in a study of over 110,000 women.
- ASCO presented the study at its 2026 Annual Meeting, and the results were published in JCO Oncology Practice.
- Elizabeth McDonald said the observational results are promising but not definitive, and her team plans a multisite clinical trial for high‑risk women.
- Ozempic and related GLP‑1 drugs are now among the most prescribed weight‑loss medications in the United States.
Why it matters: High‑risk women now have a preventive option under clinical trial, and the healthcare system anticipates lower breast‑cancer treatment costs if the 30% risk reduction is confirmed.
Ask SkimNews
